Analysis of SIB Data Subgroup
Analysis of SIB Data Bibliography
Working Group Goal:
Review current status and develop consensus regarding guiding principles and considerations when analyzing existing SIB data at the study, program and meta-analytic level and identification of gaps in current analytic approaches
Possible Activities:
–Review approaches for summarizing and analyzing clinical trial and project level data
- Summarization of SIB data without respect to treatment
- Analysis of SIB data in association with treatment
- Aggregation of SIB data with other study endpoints (eg, MADRS)
- Use of common data elements
- Relationship between SIB assessments and AE reporting
- Meta-analysis/network analysis of existing large datasets
–Review approaches for leveraging big data for SIB datasets and identifying emerging opportunities
–Identify challenges in assembling and analyzing large SIB datasets
Sub-group Members:
Munaf Ali, Munaf Ali Consultancy
John Davies, GSK
Bryan Dirks, Shire
Sarah DuBrava, Pfizer
Rebecca Evans, Parexel
Michael Federico, ERT
Andrew Freeman, Univ of Nevada, Las Vegas
Mark Gordon, Boehringer-Ingelheim
Pilar Lim, Janssen
Cristiana Mayer, Janssen
Mary Nilsson, Lilly
Jill Rasmussen, psi-napse
Madhukar Trivedi, Univ of Texas SWMC
Christine Ulbricht, UMass Medical School
Robieson Weining, AbbVie
Anna van Meter, Einstein College of Medicine
Benedetto Vitiello, NIMH
Jun Zhao, AbbVie